
    
        <!DOCTYPE html>
        <html lang="hu-HU" data-website-id="1" data-oe-company-name="HBS Medical">
            
<!-- Mirrored from hbs.hu/slides/slide/new-frontiers-in-intravesical-therapies-and-drug-delivery-2006-53 by HTTrack Website Copier/3.x [XR&CO'2014], Mon, 31 May 2021 16:08:07 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
                <meta charset="utf-8"/>
                <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1"/>
                <meta name="viewport" content="width=device-width, initial-scale=1, user-scalable=no"/>

                <title>New Frontiers in Intravesical Therapies and Drug Delivery 2006 | HBS</title>
                <link type="image/x-icon" rel="shortcut icon" href="../../web/image/website/1/favicon/index.html"/>

                <script type="text/javascript">
                    var odoo = {
                        csrf_token: "f2e9a41588799d043a772b21ddc3189150ea199fo",
                    };
                </script>

                
            <meta name="generator" content="Odoo"/>

            
            
            
            
            
            
                
                
                
                    
                        <meta property="og:type" content="website"/>
                    
                        <meta property="og:title" content="New Frontiers in Intravesical Therapies and Drug Delivery 2006"/>
                    
                        <meta property="og:site_name" content="HBS Medical"/>
                    
                        <meta property="og:url" content="https://hbs.hu/slides/slide/new-frontiers-in-intravesical-therapies-and-drug-delivery-2006-53"/>
                    
                        <meta property="og:image" content="https://hbs.hu/web/image/slide.slide/53/image_thumb"/>
                    
                        <meta property="og:description"/>
                    
                
                
                
                    
                        <meta name="twitter:card" content="summary_large_image"/>
                    
                        <meta name="twitter:title" content="New Frontiers in Intravesical Therapies and Drug Delivery 2006"/>
                    
                        <meta name="twitter:image" content="https://hbs.hu/web/image/slide.slide/53/image_thumb"/>
                    
                        <meta name="twitter:description"/>
                    
                
            

            
            
                
                    <link rel="alternate" hreflang="hu" href="new-frontiers-in-intravesical-therapies-and-drug-delivery-2006-53.html"/>
                
            

            <script type="text/javascript">
                odoo.session_info = {
                    is_admin: false,
                    is_system: false,
                    is_frontend: true,
                    translationURL: '/website/translations',
                    is_website_user: true,
                    user_id: 4
                };
                
            </script>

            <link type="text/css" rel="stylesheet" href="../../web/content/521-3ab7b2c/1/web.assets_common.0.css"/>
            <link type="text/css" rel="stylesheet" href="../../web/content/599-e81acc7/1/web.assets_frontend.0.css"/>
            <link type="text/css" rel="stylesheet" href="../../web/content/600-e81acc7/1/web.assets_frontend.1.css"/>
            
            
            

            <script type="text/javascript" src="../../web/content/524-3ab7b2c/1/web.assets_common.js"></script>
            <script type="text/javascript" src="../../web/content/603-e81acc7/1/web.assets_frontend.js"></script>
            
            
            
        
            </head>
            <body>
                
            
        
            
        
        
            
                
                    
                
                
            
        
        
    
    

            
            
        
    
            
          
        <link rel="stylesheet" type="text/css" href="../../sh_cookie_notice/static/src/css/cookieconsent.min.css"/>
        <script type="text/javascript" src="../../sh_cookie_notice/static/src/js/cookieconsent.min.js"></script>
        

	
	<script type="text/javascript"> 

	 window.addEventListener("load", function(){
 
	var sh_msg = String("Az HBS weboldala sütiket használ a weboldal működtetése, használatának megkönnyítése, a weboldalon végzett tevékenység nyomon követése és releváns ajánlatok megjelenítése érdekében.");
	var sh_esc_msg = encodeURIComponent(sh_msg);
	sh_esc_msg = decodeURIComponent(sh_esc_msg); 
	
  	window.cookieconsent.initialise({
	  "palette": {
	    "popup": {
	      "background": "#000" 
	    },
	    "button": {
	      "background": "#f1d600"
	    }
	  },
	  
	  	  "position": "top",
	  
	
	  
	  "content": {
	    "message": sh_esc_msg,
	    "dismiss": "Elfogadom",
	    "allow": "allow",
	    "link": "Adatvédelmi tájékoztató",
	    "href": "/adatkezelesi-tajekoztato"
	  }
	})});
    </script>
 
   
    <div id="wrapwrap" class="   ">
                <header class=" o_affix_enabled">
                    <nav class="navbar navbar-expand-md navbar-light bg-light">
                        <div class="container">
                            <a href="../../index.html" class="navbar-brand logo">
            <span role="img" aria-label="Logo of HBS Medical" title="HBS Medical"><img src="../../web/image/res.company/1/logo66cf.png?unique=866a03a" class="img img-fluid"/></span>
        </a>
    <button type="button" class="navbar-toggler" data-toggle="collapse" data-target="#top_menu_collapse">
                                <span class="navbar-toggler-icon"></span>
                            </button>
                            <div class="collapse navbar-collapse" id="top_menu_collapse">
                                <ul class="nav navbar-nav ml-auto text-right o_menu_loading" id="top_menu">
                                    
        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../index.html" class="nav-link ">
            <span>HBS Medical</span>
        </a>
    </li>
    

        
            
    
    <li class="nav-item">
        <a role="menuitem" href="https://covid-19.hbs.hu" class="nav-link " target="_blank">
            <span>COVID-19</span>
        </a>
    </li>
    

        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../blog/hirek-esemenyek-1.html" class="nav-link ">
            <span>Hírek</span>
        </a>
    </li>
    

        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../aboutus.html" class="nav-link ">
            <span>Kapcsolat</span>
        </a>
    </li>
    

        
    
                                    
                                </ul>
                            </div>
                        </div>
                    </nav>
                </header>
                <main>
                    
        
        <div class="container mt16">
            <div class="row">
                <div class="col-xl-8 col-lg-8 col-md-12 col-12">
                    

                    <div>
                            
                        <div class="embed-responsive embed-responsive-4by3 embed-responsive-item mb8">
                            <iframe src="../embed/532679.html?page=1" class="o_wslides_iframe_viewer" allowFullScreen="true" height="315" width="420" frameborder="0"></iframe>
                        </div>
                        
                        <div class="row">
                            <h4 class="col-lg-6">New Frontiers in Intravesical Therapies and Drug Delivery 2006</h4>
                            <div class="col-lg-6">
                                <div clas="row">
                                    
                                </div>
                            </div>
                        </div>
                        <div class="row">
                            <div class="col-md-8 col-12">
                                <div class="float-left">
                                    <a href="../nyilvanos-anyagok-1.html" title="Channel Nyilvános anyagok" aria-label="Channel Nyilvános anyagok">
                                        <i class="fa fa-circle-o fa-5x" style="color: #875A7B;font-weight: bold;"></i>
                                    </a>
                                </div>
                                <div style="margin-left: 80px">
                                    <p>
                                        <a href="../nyilvanos-anyagok-1.html">Nyilvános anyagok</a>
                                        
                                            <span> / </span>
                                            <a href="../nyilvanos-anyagok-1/category/szakirodalmi-cikkek-3.html">Szakirodalmi cikkek</a>
                                        
                                    </p>
                                    <div>
                                        
        <div class="input-group js_follow" data-id="1" data-object="slide.channel" data-follow="off">
            <input type="email" name="email" class="js_follow_email form-control" placeholder="emailje..."/>
            <div class="input-group-append">
                <button href="#" class="btn btn-secondary js_unfollow_btn">Leiratkozás</button>
                <button href="#" class="btn btn-primary js_follow_btn">Feliratkozás</button>
            </div>
        </div>
    
                                    </div>
                                </div>
                            </div>
                            <div class="col-md-4 d-none d-md-block">
                                <div class="text-right">
                                    <b class="h3 text-muted">1127</b> <span class="text-muted small">views</span>
                                </div>
                                
                                <div class="progress mb0" style="height: 2px;">
                                    <div class="progress-bar" role="progressbar" aria-valuenow="0" aria-valuemin="0" aria-valuemax="100" style="width: 0%;">
                                        <span class="sr-only">0 Likes</span>
                                    </div>
                                </div>
                                <div class="text-muted mt4">
                                    <div class="float-right mb16 text-right">
                                        <span class="oe_slide_js_like" data-href="/slides/slide/like" tabindex="0" data-toggle="popover" data-user-id="4" data-public-user="True" data-slide-id="53">
                                            <i class="fa fa-thumbs-up fa-1x" role="img" aria-label="Likes" title="Likes"></i>
                                            0
                                        </span>
                                        <span class="oe_slide_js_unlike" data-href="/slides/slide/dislike" tabindex="0" data-toggle="popover" data-user-id="4" data-public-user="True" data-slide-id="53">
                                            <i class="fa fa-thumbs-down fa-1x" role="img" aria-label="Dislikes" title="Dislikes"></i>
                                            0
                                        </span>
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="mt8 mb32">
                            <ul class="nav nav-tabs" role="tablist">
                                <li class="nav-item">
                                    <a href="#about" aria-controls="about" role="tab" data-toggle="tab" class="nav-link active">
                                        <i class="fa fa-home"></i> About
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#share" aria-controls="share" class="nav-link" role="tab" data-toggle="tab">
                                        <i class="fa fa-share-alt"></i> Share
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#discuss" aria-controls="discuss" role="tab" data-toggle="tab" class="nav-link">
                                        <i class="fa fa-comments-o"></i> Comments
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#transcript" aria-controls="transcript" class="nav-link" role="tab" data-toggle="tab">
                                        <i class="fa fa-align-justify"></i> Transcript
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#statistic" aria-controls="statistic" class="nav-link" role="tab" data-toggle="tab">
                                        <i class="fa fa-bar-chart"></i> Statistics
                                    </a>
                                </li>
                            </ul>
                            <div class="tab-content" style="padding: 20px 5px 5px 5px; word-wrap: break-word;">
                                <div role="tabpanel" id="about" class="tab-pane fade active in">
                                    
                                </div>
                                <div role="tabpanel" class="tab-pane fade" id="share">
                                    
    <h4 class="mt0">Share on Social Networks</h4>
    
    <div>
        <a class="o_slides_social_share" social-key="facebook" aria-label="Share on Facebook" title="Share on Facebook" href="https://www.facebook.com/sharer/sharer.php?u=https://hbs.hu/r/Pqw"><i class="fa fa-facebook-square fa-2x"></i></a>
        <a class="o_slides_social_share" social-key="twitter" aria-label="Share on Twitter" title="Share on Twitter" href="https://twitter.com/intent/tweet?text=New%20Frontiers%20in%20Intravesical%20Therapies%20and%20Drug%20Delivery%202006&amp;url=https://hbs.hu/r/Pqw"><i class="fa fa-twitter fa-2x"></i></a>
        <a social-key="linkedin" class="o_slides_social_share" aria-label="Share on LinkedIn" title="Share on LinkedIn" href="https://www.linkedin.com/shareArticle?mini=true&amp;url=https://hbs.hu/r/Pqw&amp;title=New%20Frontiers%20in%20Intravesical%20Therapies%20and%20Drug%20Delivery%202006&amp;"><i class="fa fa-linkedin fa-2x"></i></a>
        <a class="o_slides_social_share" social-key="gplus" aria-label="Share on Google Plus" title="Share on Google Plus" href="https://plus.google.com/share?url=https://hbs.hu/r/Pqw"><i class="fa fa-google-plus-square fa-2x"></i></a>
    </div>

    <h4 class="mt-3">Share Link</h4>
    <input type="text" class="form-control" readonly="readonly" onClick="this.select();" value="new-frontiers-in-intravesical-therapies-and-drug-delivery-2006-53.html"/>
    <span class="form-text">Use permanent link to share in social media</span>

                                    
    <h4 class="mt-3">Share with a friend</h4>
    
    
        <p>Please <a href="../../web/login.html?redirect=https://hbs.hu/slides/slide/new-frontiers-in-intravesical-therapies-and-drug-delivery-2006-53"> login </a> to send this document by email!</p>
    

                                    
                                        
    <div class="oe_slide_js_embed_code_widget">
        <h4 class="mt0">Embed in your website</h4>
        <div class="form-group">
            <textarea class="form-control slide_embed_code" readonly="readonly" onClick="this.select();">&lt;iframe src=&quot;https://hbs.hu/slides/embed/53?page=1&quot; class=&quot;o_wslides_iframe_viewer&quot; allowFullScreen=&quot;true&quot; height=&quot;315&quot; width=&quot;420&quot; frameborder=&quot;0&quot;&gt;&lt;/iframe&gt;</textarea>
        </div>
        <div class="form-group">
            <div class="form-text col-xl-3 col-lg-3 col-md-6 col-6">Select page to start with</div>
            <div class="input-group col-xl-3 col-lg-3 col-md-6 col-6">
                <input type="number" value="1" class="form-control"/>
            </div>
        </div>
    </div>

                                    
                                </div>
                                
                                <div role="tabpanel" id="discuss" class="tab-pane fade">
                                    
        <div id="discussion" class="d-print-none o_portal_chatter o_not_editable p-0" data-res_model="slide.slide" data-res_id="53" data-pager_step="10" data-allow_composer="1">
        </div>
    
                                </div>
                                <div role="tabpanel" class="tab-pane fade oe_slides_transcript" id="transcript">
                                    
                                        
                                            <p>10. [23]  Phipps  JB,  Padmanabhan  RV,  Lattin  GA.  Iontophoretic delivery of model inorganic and drug ions.  J Pharm Sci 1989;78:365–9. [24]  Lugnani F, Mazza G, Cerulli N, Rossi C, Stephen RL. Ion- tophoresis of drugs in the bladder wall: equipment and preliminary studies. Artif Organs 1993;17:8–17. [25]  Gurpinar T, Truong LD, Wong HY, Griffith DP. Electromo- tive drug administration to the urinary bladder: an animal model and preliminary results. J Urol 1996;156:1496–501. [26]  Turnell WJ. Therapeutic action of constant current. Proc R Soc Med 1921;14:41–52. [27]  Sloan JB, Soltani K. Iontophoresis in dermatology. J Am Acad Dermatol 1986;15:617–84. [28]  Glass  JM,  Stephen  RL,  Jacobson  SC.  The  quantity  and distribution of radiolabeled dexamethasone delivered to tissue by iontophoresis. Int J Dermatol 1980;19:519–24. [29]  Di Stasi SM, Giannantoni A, Vespasiani G, et al. Intrave- sical   electromotive   administration   of   oxybutynin   in patients  with  detrusor  hyperreflexia  unresponsive  to standard anticholinergic regimens. J Urol 2001;165:491–8. [30]  Di Stasi SM, Giannantoni A, Navarra P, et al. Intravesical oxybutynin: mode of action assessed by passive diffusion and electromotive administration with pharmacokinetics of oxybutynin and N-desethyl oxybutynin. J Urol 2001;166: 2232–6. [31]  Di Stasi SM, Giannantoni A, Stephen RL, et al. Intravesical electromotive   mitomycin   C   versus   passive   transport mitomycin  C  for  high  risk  superficial  bladder  cancer:  a prospective randomized study. J Urol 2003;170:777–82. [32]  Di Stasi SM, Giannantoni A, Giurioli A, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomized con- trolled trial. Lancet Oncol 2006;7:43–51. [33]  Colombo R, Brasi M, Da Pozzo L, et al. Thermo-chemother- apy and electromotive drug administration of mitomycin C in superficial bladder cancer eradication. A pilot study on marker lesions. Eur Urol 2001;39:95–100. [34]  Di Stasi SM, Giannantoni A, Massoud R, et al. Comparative bladder  wall  tissue  levels  of  resiniferatoxin.  In:  Proc. Abstract  Book  of  the  ICS  34th  Annual  meeting,  Paris, 25–27 August 2004 (abstract no. 577). [35]  Di Stasi S, Giannantoni A, Massoud R, Navarra P, Vespa- siani G, Porena M, Stephen R. Stability of resiniferatoxin stock solution. Eur Urol Suppl 2004;3(2):106 (abstract no. 414). [36]  Di Stasi SM, Giannantoni A, Stephen RL, et al. A prospec- tive randomized study using transdermal electromotive administration  of  verapamil  and  dexamethasone  for Peyronie’s disease. J Urol 2004;171:1605–8. [37]  Riedl CR, Daha LK, Knoll M, Pflueger H. Betanechol in the restitution  of  the  acontractile  detrusor:  a  prospective, randomized,   double-blind,    placebo-controlled   study. Neurourol Urodyn 2002;21:376 (abstract no. 71A). [38]  Di Stasi SM, Giannantoni A, Navarra P, et al. The stability of lidocaine and epinephrine solutions exposed to electric current and comparative administrations rates of the two drugs into pig bladder wall. Urol Res 2003;31:169–76. [39]  Massoud R, Federici G, Casciani S, et al. Extraction and determination of oxybutynin in human bladder samples by  reversed-phase  high-performance  liquid  chromato- graphy. J Chromatogr B 1999;734:163–7. [40]  Di  Stasi  SM,  Giannantoni  A,  Massoud  R,  Cortese  C, Vespasiani  G,  Micali  F.  Electromotive  administration  of oxybutynin  into  the  human  bladder  wall.  J  Urol  1997; 158:228–33. [41]  Di  Stasi SM,  Vespasiani  G,  Giannantoni  G,  Massoud R, Dolci S, Micali F. Electromotive delivery of mitomycin C into the  human  bladder  wall.  Cancer  Res 1997;57:875– 80. [42]  Di Stasi SM, Giannantoni A, Massoud R, et al. Electromo- tive versus passive diffusion of mitomycin C into human bladder wall: concentration-depth profiles studies. Can- cer Res 1999;59:4912–8. [43]  Brausi M, Campo B, Pizzocaro G, et al. Intravesical elec- tromotive administration of drugs for treatment of super- ficial  bladder:  a  comparative  phase  II  study.  Urology 1998;51:506–9. [44]  Stenzl A, Eder I, Kostron H, Klocker H, Bartsch G. Electro- motive diffusion (EMD) and photodynamic therapy with delta-aminolevulinic acid (delta-ALA) for superficial blad- der cancer. J Photochem Photobiol B 1996;36:233–6. [45]  Jewett MAS, Valiquette L, Sampson HA, Katz J, Fradet Y, Redelmeier  DA.  Electromotive  drug  administration  of lidocaine as  an alternative  anesthesia for transurethral surgery. J Urol 1999;482–5. [46]  Fontanella UA, Rossi CA, Stephen RL. Bladder and urethral anaesthesia   with   electromotive   drug   administration (EMDA): a technique for invasive endoscopic procedures. Br J Urol 1997;79:414–20. [47]  Schurch B, Reitz A, Tenti G. Electromotive drug adminis- tration  of  lidocaine  to  anesthetize  the  bladder  before botulinum-A  toxin  injections  into  the  detrusor.  Spinal Cord 2004;42:338–41. [48]  Dasgupta P, Fowler CJ, Hoverd P, et al. Does electromotive drug administration (EMDA) with lignocaine before intra- vesical   capsaicin   confer   benefit?   J   Urol   1997;157:186 (abstract no. 724). [49]  Riedl C, Knoll M, Plas E, Stephen RL, Pfluger H. Intravesical electromotive  drug  administration  for  the  treatment  of non-infectious  chronic  cystitis.  Int  Urogynecol  J  Pelvic Floor Dysfunct 1997;8:134–7. [50]  Riedl  C,  Knoll  M,  Plas  E,  Pfluger  H.  Electromotive  drug administration and hydrodistention for the treatment of interstitial cystitis. J Endourol 1998;12:269–72. [51]  Rosamilia A, Dwyer PL, Jbson J. Electromotive drug admin- istration  of  lidocaine  and  dexamethasone  followed  by cystodistension  in  women  with  interstitial  cystitis.  Int Urogynecol J Pelvic Floor Dysfunct 1997;8:142–5. [52]  Hinkel A, Pannek J. Transient ischemic attack after elec- tromotive drug administration for chronic non-infectious cystitis:  report  of  two  similar  cases.  Neurourol  Urodyn 2004;23:180–2. [53]  Rose EA, Azevedo KJ, Payne CK. Office bladder distension with electromotive drug administration (EMDA) is equiva- lent  to  distension  under  general  anesthesia.  BMC  Urol 2005;5:14–8. [54]  Rose AE, Payne CK, Azevedo K. Pilot study of the feasibility of in-office bladder distention using electromotive drug european urology 50 (2006) 1183–1193 1192 </p>
                                        
                                            <p>11. administration  (EMDA).  Neurourol  Urodyn  2005;24:254– 60. [55]  Sasaki M, Hashimoto H, Yachiku S. Studies on enhance- ment  of  drug  absorption  through  the  bladder  mucosa. Nippon Hinyokika Gakkai Zasshi 1994;85:1353–62. [56]  Hashimoto H, Yachiku S, Watanabe Y, et al. Postoperative intravesical installation of tetrahydropyranyl-adriamycin (THP) and cytosine arabinoside (CA) for superficial blad- der  cancer:  clinical  results  of  prophylactic  effects  on recurrence. Gan To Kagaku Ryoho 1994;21:833–8. [57]  Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active pro- tein into the mouse. Science 1999;285:1569–72. [58]  Nielsen  PE.  Gene  targeting  using  peptide  nucleic  acid. Methods Mol Biol 2005;288:343–58. [59]  Pooga M, Land T, Bartfai T, Langel U. PNA oligomers as tools for specific modulation of gene expression. Biomol Eng 2001;17:183–92. [60]  Frangos DN, Killion JJ, Fan D, et al. The development of liposomes containing interferon alpha for the intravesical therapy  of  human  superficial  bladder  cancer.  J  Urol 1990;143:1252–6. [61]  Lazzeri M, Spinelli M, Beneforti P, Malaguti S, Giardiello G, Turini  D.  Intravesical  infusion  of  resiniferatoxin  by  a temporary in situ drug delivery system to treat interstitial cystitis: a pilot study. Eur Urol 2004;45:98–102. [62]  Shurafa M, Shumaker E, Cronin S. Prostaglandin F2-alpha bladder irrigation for control of intractable cyclophospha- mide-induced   hemorrhagic   cystitis.   J   Urol   1987;137: 1230–1. [63]  Trigg ME, O’Reilly J, Rummelhart S, Morgan D, Holida M, de  Alarcon  P.  Prostaglandin  E1  bladder  instillations  to control severe hemorrhagic cystitis. J Urol 1990;143:92–4. [64]  Miller LJ, Chandler SW, Ippoliti CM. Treatment of cyclo- phosphamide-induced hemorrhagic cystitis with prosta- glandins. Ann Pharmacother 1994;28:590–4. [65]  Ronneberger B, Kao WY, Anderson JM, Kissel T. In vivo biocompatibility study of ABA triblock copolymers con- sisting of poly(L-lactic-co-glycolic acid) A blocks attached to central poly(oxyethylene) B blocks. J Biomed Mater Res 1996;30:31–40. [66]  Jeong B, Bae YH, Kim SW. Drug release from biodegrad- able injectable thermosensitive hydrogel of PEG-PLGA- PEG  triblock  copolymers.  J  Control  Release  2000;63: 155–63. [67]  Jeong B, Bae YH, Kim SW. In situ gelation of PEG-PLGA-PEG triblock  copolymer  aqueous  solutions  and  degradation thereof. J Biomed Mat Res 2000;50:171–7. [68]  Tyagi P, Li Z, Chancellor MB, de Groat WC, Yoshimura N, Huang L. Sustained intravesical drug delivery using ther- mosensitive hydrogel. Pharm Res 2004;21:832–7. [69]  Bangham AD. A correlation between surface charge and coagulant   action   of   phospholipids.   Nature   1961;192: 1197–8. [70]  Johnson JW, Nayar R, Killion JJ, von Echenbach AC, Fidler IJ. Bindings of liposomes to human bladder tumor epithe- lial cell lines: implications for an intravesical drug deliv- ery system for the treatment of bladder cancer. Sel Cancer Ther 1989;5:147–55. [71]  Tyagi  P,  Chancellor  MB,  Li  Z,  et  al.  Urodynamic  and immunohistochemical evaluation of intravesical capsai- cin  delivery  using  thermosensitive  hydrogel  and  lipo- somes. J Urol 2004;171:483–9. [72]  Fraser MO, Chuang YC, Tyagi P, et al. Intravesical lipo- some administration—a novel treatment for hyperactive bladder in the rat. Urology 2003;3:656–63. european urology 50 (2006) 1183–1193 1193 Editorial Comment Karel Everaert, Department of Urology, Ghent University Hospital, Belgium <a href="../../cdn-cgi/l/email-protection.html" class="__cf_email__" data-cfemail="9af1fbe8fff6b4ffecffe8fbffe8eedacffdfff4eeb4f8ff">[email&#160;protected]</a> This comprehensive article on intravesical thera- pies reviews the less accessible, nonmedical litera- ture for the urologist and links the information to clinical practice and empirical therapies for which I offer my congratulations. The physical and chemi- cal properties of the urothelium are worth further study in the future and empirically found applica- tions  need  confirmation  in  randomised  trials  so that a larger introduction into clinical practice is possible. Improving anaesthesia of the bladder is useful for general urologic practice. In functional urology, interstitial cystitis and the overactive blad- der  are  demanding  indications  for  any  improve- ment  in  the  intravesical  route  (botulinum  toxin, resiniferatoxin,  dimethyl  sulfoxide,  oxybutynin, etc). Electromotive drug administration (EMDA) is not  routinely  used  in  clinical  practice  and  intra- luminal drug delivery devices need confirmation in the literature along with pertinent indications. New chemical  approaches  are  discussed  but  are  still considered experimental. This review is hopefully the impetus for a large series of studies, publica- tions, and new developments. </p>
                                        
                                            <p>9. achieve  localised  therapy  with  negligible  penetra- tion to other organs. Earlier it was reported that liposomes can form a film  on  the  cell  surface  and  have  been  tested  as possible   therapeutic   agents   to   promote   wound healing. Such reports prompted evaluation of empty liposomes  devoid  of  any  drug  in  a  rat  model  of bladder hyperactivity. Liposomes alone were able to partially reverse the high urinary frequency induced by PS/KCl. These observations suggested that lipo- somes  might  enhance  the  barrier  properties  of  a dysfunctional   uroepithelium   and   increase   resis- tance to irritant penetration. 8.    Conclusions The  lower  urinary  tract  is  ideally  suited  for  mini- mally invasive intravesical therapy that would limit the  risk  of  systemic  side-effects.  Although  treat- ment with intravesical passive delivery of drugs is commonly  used  today  in  patients  on  intermittent catheterisation,  new  physical  approaches  such  as EMDA or in situ delivery systems and bioadhesive liposomes  may  expand  intravesical  therapy  and drug administration to many bladder diseases. New agents  modulating  bladder  neurotransmitters  and neuroreceptors are being discovered, and they may be  appropriate  for  advanced  intravesical  therapy. Research to expand the knowledge of chemical and physical  properties  of  the  bladder  and  processes regulating   drug   transport   across   biologic   mem- branes is needed to make this a reality. References [1]  Brendler TB, Appell RA, Lopez MA, et al. Pharmacokinetic evaluation of intravesical oxybutynin: bolus and contin- uous delivery. J Urol 2001;165:252 (abstract no. 1039). [2]  Lazzeri  M,  Spinelli  M,  Zanollo  L,  Turini  D.  Intravesical vanilloids and neurogenic incontinence: ten years experi- ence. Urol Int 2004;72:145–9. [3]  Giannantoni A, Di Stasi SM, Stephen RL, et al. Intravesical capsaicin versus resiniferatoxin in patients with detrusor hyperreflexia:  a  prospective  randomized  study.  J  Urol 2002;167:1710–4. [4]  de Seze M, Wiart L, de Seze MP, et al. Intravesical capsaicin versus   resiniferatoxin   for   the   treatment   of   detrusor hyperreflexia  in  spinal  cord  injured  patients:  a  double- blind,  randomized,  controlled  study.  J  Urol  2004;171: 251–5. [5]  Tyagi  P,  Chancellor  MB,  Li  Z,  et  al.  Urodynamic  and immunohistochemical evaluation of intravesical capsai- cin  delivery  using  thermosensitive  hydrogel  and  lipo- somes. J Urol 2004;171:483–9. [6]  Parsons  CL,  Lilly  JD,  Stein  P.  Epithelial  dysfunction  in nonbacterial  cystitis  (interstitial  cystitis).  J  Urol  1991; 145:732–5. [7]  Lewis SA. Epithelial electrophysiology. In: Wills NK, Reuss L, Lewis SA, editors. Epithelial transport: a guide to meth- ods and experimental analysis. London: Chapman &amp; Hall; 1996. p. 93–117. [8]  Lewis SA, Diamond JM. Na + transport by rabbit urinary bladder, a tight epithelium. J Membr Biol 1976;28:1–40. [9]  Ping H, Meyers S, Liang F, et al. Role of membrane proteins in permeability barrier function: uroplakin ablation ele- vates urothelial permeability. Am J Physiol Renal Physiol 2002;283:200–7. [10]  Negrete HO, Lavelle JP, Berg J, Lewis SA, Zeidel ML. Perme- ability   properties   of   the   intact   mammalian   bladder epithelium. Am J Physiol 1996;271:886–94. [11]  Lewis  SA.  Everything  you  wanted  to  know  about  the bladder epithelium but were afraid to ask. Am J Physiol Renal Physiol 2000;278:867–74. [12]  Hohlbrugger  G,  Lentsch  P.  Intravesical  ions,  osmolality and  pH  influence  the  volume  pressure  response  in  the normal  rat  bladder  and  this  is  more  pronounced  after DMSO. Eur Urol 1985;11:127–30. [13]  Mann FC, Magoun JAH. Absorption from the urinary blad- der. Am J Med Sci 1923;166:96–106. [14]  Kerec M, Bogataj M, Veranic P, Mrhar A. Permeability of pig urinary bladder wall: the effect of chitosan and the role of calcium. Eur J Pharm Sci 2005;25:113–21. [15]  Holz R, Finkelstein A. The water and nonelectrolyte per- meability induced in thin lipid membranes by the polyene antibiotics  nystatin  and  amphotericin  B.  J  Gen  Physiol 1970;56:124–45. [16]  Chuang YC, Yoshimura N, Huang CC, Chaing PH, Chan- cellor MB. Intravesical botulinum toxin A administration produces  analgesia  against  acetic  acid  induced  bladder pain responses in rats. J Urol 2004;172:1529–32. [17]  Vemulakonda VM, Somogyi GT, Kiss S, Salas NA, Boone TB, Smith CP. Inhibitory effects of intravesically applied botulinum toxin a in chronic bladder inflammation. J Urol 2005;173:621–4. [18]  Lavelle J, Meyers S, Ramage R, et al. Bladder permeability barrier: recovery from selective injury of surface epithe- lial cells. Am J Physiol Renal Physiol 2002;283:242–53. [19]  Cetinel S, Ercan F, Sirvanci S, et al. The ameliorating effect of melatonin on protamine sulfate induced bladder injury and its relationship to interstitial cystitis. J Urol 2003;169: 1564–8. [20]  Aydin H, Ercan F, Cetinel S, San T. Morphological exam- ination  of  the  effects  of  defibrotide  on  experimentally induced  bladder  injury  and  its  relation  to  interstitial cystitis. Urol Res 2001;29:263–71. [21]  Melchior D, Packer CS, Johnson TC, Kaefer M. Dimethyl sulfoxide: does it change the functional properties of the bladder wall? J Urol 2003;170:253–8. [22]  See WA, Xia Q. Regional chemotherapy for bladder neo- plasms using continuous intravesical infusion of doxor- ubicin: impact of concomitant administration of dimethyl sulfoxide  on  drug  absorption  and  antitumor  activity. J Natl Cancer Inst 1992;84:510–5. european urology 50 (2006) 1183–1193 1191 </p>
                                        
                                            <p>4. Many factors, including pressure and concentra- tion  gradients,  time  of  exposure,  partition  coeffi- cient, molecular weight and chemical structure, pH degree   of   ionisation,   and   urinary   output   rate, interact to produce different transport rates. It has been observed that recruitment of electro- kinetic forces accelerates drug administration rates across  biologic  membranes  and  into  underlying tissues [23] . The term ‘‘electromotive drug admin- istration’’  (EMDA)  describes  the  transport  of  all water-soluble   drugs   under   the   influence   of   an electric field and, unlike PD, is most effective when dealing with an ionised drug, where the rate of drug transport  is  proportional  to  the  intensity  of  the applied  current,  which  largely  overrides  all  other variables [23,24] . The   idea   of   using   electric   current   to   allow transcutaneous  drug  penetration  can  probably  be attributed to the work done by Veratti in 1747 [25] . The concept of iontophoresis was first described in the  mid-18th  century.  However,  it  was  not  until Leduc’s  experimentation  in  1908  that  researchers realised the importance of the differences between positive and negative ions and adopted this techni- que for therapeutic uses. In recent years, iontophor- esis has been used for local anaesthesia of the skin [26] ,  to  administer  corticosteroids  to  joints  and tendons  involved  in  inflammatory  processes [27] , and  for  regular  transcutaneous  administration  of drugs [28] . EMDA has been recently applied in the treatment of  bladder  pathologies  and  dysfunctions.  Labora- tory and clinical studies have been conducted on intravesical  electromotive  delivery  of  oxybutynin [29,30] ,  mitomycin  C  (MMC) [31–33] ,RTX [34,35] , verapamil  and  dexamethasone [36] ,  bethanecol [37] , and lidocaine and epinephrine [38] ( Tables  1 and 2 ). Laboratory studies have been performed, first of all,  to  identify  a  sensitive  method  to  determine tissue concentrations of different drugs after either PD or electromotive administration ( Table 1 ). Massoud   et   al.   found   that   high-performance liquid  chromatography  (HPLC),  equipped  with  a diode-array  spectrophotometric  detector,  an  elec- trochemical  detector  and  reversed-phase  column, european urology 50 (2006) 1183–1193 1186 Table 1 – Laboratory studies of drug administration by EMDA or passive delivery Authors [ref]                         Aims to assess                     Tissue/material                       Results                    Advantages/problems Lugnani et al. [24] Lidocaine + epinephrine penetration with EMDA Cadaveric human bladder Staining extends into the muscolaris in all bladders EMDA may have applications to treat bladder diseases Gurpinar et al. [25] Methylene blue penetration with EMDA Dog bladder                      Significant submucosal and muscolaris methylene blue penetration EMDA may have applications to treat bladder diseases Di Stasi et al. [41] (a) MMC concentrations after passive diffusion or EMDA Human bladder                EMDA/MMC reduces variability in drug delivery rate Tissue undamaged and viable, no modification in drug structure (b) Effects of EMDA on tissue viability and on MMC structure Di Stasi et al. [40] Oxybutynin concentrations after both passive delivery or EMDA Human bladder                After EMDA: mean oxybutynin tissue concentrations significantly higher Tissue undamaged and viable, no modification in drug structure Di Stasi et al. [42] MMC concentration-depth profiles after passive diffusion or EMDA Human bladder                EMDA significantly enhances MMC transport into all bladder wall layers Tissue undamaged and viable, no modification in drug structure Massoud et al. [39] Oxybutynin extraction and determination by HPLC Human bladder                EMDA significantly enhances oxybutynin penetration Simple and cost effective; no internal standard required Di Stasi et al. [38] (a) Stability of lidocaine and epinephrine over time (mass spectrometry) Pig bladder                        Lidocaine and epinephrine remain stable for 1 d; EMDA accelerates lidocaine and epinephrine transport In vitro results support clinical studies (b) Transport rates with passive diffusion or EMDA Di Stasi et al. [35] Stability of RTX stock solution by HPLC Plastic material/glass      RTX stock solutions: better stability if stored at  4 8 C in the dark Material for RTX storage is not important Di Stasi et al. [34] RTX concentrations of after passive delivery or EMDA Pig bladder                        RTX bladder concentrations significantly higher Large coefficient of variation with both techniques EMDA = electromotive drug administration; MMC = mitomycin C; HPCL = high-performance liquid chromatography; RTX = resiniferatoxin. </p>
                                        
                                            <p>6. european urology 50 (2006) 1183–1193 1188 Table 2 – Clinical trials of intravesical drug administration by EMDA or passive delivery Authors [ref]                             Trials (no. of patients) Indications                                    Intravesical drug/ surgical procedure Results                                    Side-effects Lugnani et al. [24] Controlled (22)                   Bladder anaesthesia before surgery Lidocaine and epinephrine/EMDA               Pain in 16/22 patients                               In all patients: transient erythema of abdominal skin Gurpinar et al. [25] Prospective (6)                   Refractory interstitial cystitis Lidocaine and epinephrine + cystodistention Symptoms improved in 4 patients Tingling sensation on the abdominal skin Stenzl et al. [44] Prospective (6)                   Superficial bladder cancer: to evaluate the effects of d -ALA in photodynamic diagnosis and therapy PD/ d -ALA vs. EMDA/ d -ALA and photodynamic therapy 5 patients were tumor free for to up 16 mo No complications occurred Riedl et al. [49] Prospective (17)                 Noninfectious chronic cystitis             Lidocaine and dexamethasone + cystodistention No pain in 11 patients; partial resolution in 4 No complications occurred Rosamilia et al. [51] Prospective (21)                 Refractory interstitial cystitis Lidocaine and dexamethasone + cystodistention No pain in 25% of patients at 6 mo and in 63% at 2 mo No complications occurred Fontanella et al. [46] Prospective (91)                 Bladder and urethral anaesthesia before surgery EMDA/lidocaine and adrenaline                  No pain in 111 interventions                  Transient erythema of abdominal skin Brausi et al. [43] Prospective multicenter controlled (28) Superficial bladder cancer                    Passive/MMC (13 patients) vs. EMDA/MMC (15 patients) EMDA/MMC:                                               After EMDA/MMC: severe chemical cystitis in 2/15 patients; cutaneous rush in 1/15 CR: 41% vs. 41.6%; less recurrence, longer disease-free interval Dasgupta et al. [48] Prospective (8)                   Refractory neurogenic detrusor overactivity EMDA/lidocaine and epinephrine (before intravesical capsaicin) Successful                                                  No complications CR: 75% of patients; increase in functional bladder capacity from 3 to 8 mo Riedl et al. [50] Prospective (13)                 Refractory interstitial cystitis EMDA/lidocaine and dexamethasone + cystodistention No pain in 62% of patients for 4.5 mo; mean bladder capacity increased by 166% Transient erythema of abdominal skin Jewett et al. [45] Prospective multicenter (94) Bladder cancer, BPH, interstitial cystitis No anaesthesia (18 patients) vs. EMDA/lidocaine before bladder biopsy (27 patients); EMDA/lidocaine for: transuretral resection of bladder cancer (43 patients), hydrodistension and BPH (6 patients) No pain in EMDA groups                         Tingling sensation during treatment; mucosal blanching at the bladder neck Colombo et al. [33] Prospective (80)                 Superficial bladder cancer Passive/MMC (36 patients) vs. MMC/thermochemotherapy (29 patients) vs. EMDA/MMC (15 patients) CR:                                                               Local toxicity more severe after thermochemotherapy (a) Passive/MMC: 27% (b) Thermochemtherapy/ MMC: 40% (c) EMDA/MMC: 66% Di Stasi et al. [29] Prospective (10)                 Refractory neurogenic detrusor overactivity Oral oxybutynin vs. passive/oxybutynin vs. EMDA/oxybutynin + pharmacokinetic studies (oxybutynin) After EMDA/oxybutynin: significant improvements in urodynamics Transient erythema of abdominal skin in most patients </p>
                                        
                                            <p>2. 1.    Introduction The direct administration of drug solutions into the bladder overcomes systemic adverse effects of drugs used  for  bladder  disease.  Commonly  used  for  the treatment of superficial bladder cancer, intravesical drug administration, for example, oxybutynin, has also  been  used  to  treat  neurogenic  detrusor  over- activity [1] . The variability of the results obtained in different clinical studies with intravesical oxybuty- nin can be attributed to several factors related to the properties  of  the  urothelium  as  well  as  the  char- acteristics of the therapeutic agents. Recent   observations   of   several   receptors   for different  neurotransmitters  (cholinergic,  adrener- gic, purinergic, and vanilloid receptors) at the level of the urothelial cells suggest that the target sites for pharmacologic  modulation  of  bladder  dysfunction should be readily available. In any event, the ideal chemical and physical conditions for each instilled drug  solution  must  still  be  standardised.  Urine  is frequently  hypertonic  and  differs  markedly  with respect  to  blood  potassium  and  pH.  Changes  in intravesical   ions,   osmolality,   and   pH   can   alter urothelial  permeability,  increasing  or  decreasing drug penetration into the bladder wall. Furthermore,  it  seems  that  a  crucial  point  to obtain successful drug penetration is the vehicle of the drug solution to increase urothelial permeabil- ity. Normal  saline,  ethanol  at  different concentra- tions, glucidic solvents, or liposomes with hydrogel, have  been  used  for  capsaicin  and  resiniferatoxin (RTX)  intravesical  delivery,  with  different  success rates [2–5] . As  things  currently  stand,  we  do  not  know  the best  vehicle  for  each  intravesical  drug  nor  do  we know the ideal bladder conditions to perform useful intravesical treatment. Indeed, a better knowledge of  urothelial  permeability  and  of  new  systems  of delivery  could  help  to  optimise  intravesical  treat- ments. This  review  examines  the  mechanisms  under- lying  drug  transport  into  the  bladder  wall  and discusses  exciting  new  frontiers  for  intravesical therapy. 2.    Bladder urothelium: permeability and drug diffusion The main function of the urinary bladder is to store urine  while  maintaining  the  composition  of  the urine similar to that produced by the kidneys. The urothelium allows the urinary bladder to minimise alterations   in   the   composition   of   the   urine. Urothelial  cells  have  different  properties  to  per- form  this  function.  First  of  all,  the  urothelium should expose a minimum surface to intravesical volume to avoid large movements of urine compo- nents across the bladder wall. The geometry of the bladder,  which  resembles  a  sphere,  is  ideal  for obtaining a minimum epithelial surface area with respect  to  urine  volume.  Thus,  the  amount  of movement  of  substances  between  the  urine  and blood   is   reduced.   Urothelial   cells   should   be impermeable to all substances present in the urine or  blood.  Movement  across  the  urothelial  cells occurs via two parallel pathw ays: the ‘‘transcellular pathway’’ (through the cells) and the ‘‘paracellular pathway’’ (through the tight junctions and lateral intercellular  spaces) [7] .  Tight  junctions  and  cell membranes  should  be  impermeable  to  urine  or blood components, as well as to any drug contained in   both   compartments.   Modifications   of   either cellular  or  tight  junction  permeability  alter  the efficacy of the barrier properties of the urothelium. 3.    Passive permeability For  prolonged  periods,  the  mammalian  bladder  is able  to  maintain  large  gradients  for  water,  small nonelectrolytes,   ions,   protons,   and   ammonium between  the  urine  it  stores  and  blood.  It  is  well known that the bladder has a small but finite passive permeability  to  most  substances  (electrolytes  and nonelectrolytes) found in the urine and blood [9] .Itis possible  to  measure  the  ion  permeability  of  an epithelium by calculating the transepithelial electric resistance, which is caused by the parallel arrange- ment of cell resistance and tight junction resistance [10] .  Based  on  the  magnitude  of  this  resistance, epithelial cells are divided into two categories: leaky and tight epithelial cells. The bladder epithelium is considered  a  tight  epithelium [11] ,  which  has  the highest  recorded  transepithelial  resistance  of  all epithelia measured to date. The lack of ‘‘uroplakins’’ or   urothelial   plaques   (protein   particles   packed hexagonally in the apical surface of the urothelium) does not affect the function of the tight junctions between umbrella cells, but does increase urea and water permeability [8] . In essence, the apical membrane of the bladder urothelium  contributes  80%  of  the  resistance  to water flow of the epithelium as well as &gt; 95% of the resistance to fluxes of urea, ammonia, and protons. If  there  is  appreciable  permeation  of  these  sub- stances through the tight junctions, then the apical membrane  provides  an  even  higher  proportion  of the resistance across the epithelium [12] . european urology 50 (2006) 1183–1193 1184 </p>
                                        
                                            <p>7. european urology 50 (2006) 1183–1193 1189 Table 2 ( Continued ) Authors [ref]                             Trials (no. of patients) Indications                                    Intravesical drug/ surgical procedure Results                                    Side-effects Di Stasi et al. [30] Prospective (12)                 Refractory neurogenic detrusor overactivity Oral oxybutynin vs. passive/oxybutynin vs. EMDA/oxybutynin + pharmacokinetic studies (oxybutynin and N -desethyloxybutynin) After EMDA/oxybutynin: significant improvements in urodynamics Transient erythema of abdominal skin in most patients Riedl et al. [37] Prospective (25)                 Detrusor hypocontractility EMDA/bethanecol                                           EMDA/bethanecol predicts success of oral therapy in 86% of patients Bladder discomfort and pain in few cases Di Stasi et al. [31] Multicentre randomised controlled (108) Superficial bladder cancer Passive/MMC (36 patients) vs. EMDA/MMC (36 patients) vs. passive/BCG (36 pts) CR:                                                               No complications with EMDA (a) Passive/MMC: 28% (b) EMDA/MMC: 53% (c) BCG: 56% Schurch et al. [47] Prospective (38)                 Refractory neurogenic detrusor overactivity Passive/lidocaine + Botox (10 patient) vs. EMDA/lidocaine + Botox (28 patients) Mean pain score: 4.0 vs. 0.5, respectively After EMDA/lidocaine: slight or no pain during Botox injections Hinkel et al. [52] Case report (1)                   Chronic noninfectious cystitis EMDA/lidocaine + epinephrine + dexamethasone Success                                                       No complications Rose et al. [54] Prospective (21)                 Refractory interstitial cystitis Passive/lidocaine + cystodistention (10 patients) vs. EMDA/lidocaine (11 patients) + cystodistention, in the office After EMDA/lidocaine: 135% increase in bladder capacity Failure Rose et al. [53] Retrospective (21)             Refractory interstitial cystitis EMDA with cystodistention in the office vs. general anaesthesia No significant difference                         Pain persistence Di Stasi et al. [32] Prospective randomised High-risk superficial bladder cancer Passive/BCG vs. BCG + EMDA/MMC             BCG + EMDA/MMC longer disease-free interval, less recurrence, progression, and disease-specific mortality No systemic complications EMDA = electromotive  drug  administration; d -ALA = d -aminolevulinic   acid;  PD = passive  diffusion;  MMC = mitomycin  C;   CR = complete   response;  BPH = benign  prostatic   hyperplasia; BCG = bacillusCalmette-Gue  ́ rin. </p>
                                        
                                            <p>3. 4.    The ‘‘blood–urine barrier’’ An essential requirement for normal bladder func- tion is that urine components should not jeopardise the  barrier  properties  of  the  bladder [6] .  Changes within the physiologic range for urine pH or calcium or  urea  concentrations  do  not  alter  the  barrier function  of  the  urothelium,  as  determined  from measurements   of   the   transepithelial   resistance. Consequently,  acid  pH,  low  Ca ++ ,  or  high  urea increase  the  ion  permeability  of  the  urothelium [8] . In experimental studies, urine seems to be able to  influence  the  volume–pressure  response  of  the bladder; bladder capacity can be reduced by admin- istering   intravesical   solutions   of   isotonic   KCl, hypertonic NaCl, and pH 5 [9] . It can be increased by   administration   of   hypotonic   NaCl,   isotonic mannitol, and pH 8 [9] . Furthermore, extracellular K + and hyperosmolality directly depolarise smooth muscle  cells  and  generate  increased  activity  of the  detrusor,  whereas  hypo-osmolality  produces opposite changes [9] . 5.    Agents that alter urothelial permeability Several pharmacologic agents, which increase blad- der  urothelial  permeability  and  can  be  used  for clinical purposes, have been described. A number of nonphysiologic factors cause altera- tions  of  the  urothelial  barrier  function.  Bacterial products,  such  as  amphotericin  B,  nystatin,  poly- myxin  B,  and  possibly b -hemolysin,  as  well  as positively  charged  proteins  released  from  eosino- phils and found in sperm (histones and protamine), increase the ion permeability of the urothelium by interacting with the apical membrane. Acetate, propionate, butyrate, or succinate at pH 4.4, but not at pH 5.0, also alter the transepithelial permeability of rabbit urothelium [9] . The increase in transepithelial permeability due to volatile fatty acids  is  rapid  (minutes)  and  is  due,  in  part,  to  an increase in the permeability of the apical membrane to sodium and chloride [13] . 5.1.   Chitosan Chitosan is a polysaccharide composed of glucosa- mine and N -acetylglucosamine. It is regarded as a biocompatible,  biodegradable,  and  nontoxic  poly- mer.  Chitosan  can  induce  desquamation  of  pig urothelium,  which  removes  all  diffusion  barriers: glycosaminoglycans, membrane plaques, and tight junctions   of   umbrella   cells.   This   ability   has been proven in vitro on nasal, buccal, vaginal, and urinary bladder mucosa of different animals, thus making  this  polymer  a  promising  agent  in  the development  of  controlled  drug  delivery  systems [14] . 5.2.   Antibiotics Nystatin and gramicidin eliminate the apical mem- brane  as  a  resistive  element  for  water  diffusion. Nystatin  is  incorporated  into  the  lipid  bilayers  of sterol-containing  biologic  membranes  and  creates aqueous pores. This effect rapidly increases with the addition of the detergent Triton X-100 [15] . 5.3.   Protamine sulphate An  ideal  model  of  urothelial  injury  would  involve selective  damage  to  the  surface  of  urothelial  or umbrella  cells.  On  the  basis  of  its  potential  to damage  the  surface  glycosaminoglycan  layer  of urothelial  cells,  protamine  sulphate  (PS)  has  been instilled  into  bladders  in  vivo  and  the  effects  on bladder function have been evaluated [16,17] . It was demonstrated that exposure to PS in vivo causes a clear-cut  disruption  of  the  bladder  permeability barrier,  which  starts  within  1 h  of  exposure  and recovers during days 2–5 [18] . PS bladder damage can be   avoided   by   the   addition   of   intraperitoneal melatonin or intravesical defibrotide [19,20] . 5.4.   Dimethyl sulfoxide Widely  used  to  treat  interstitial  cystitis,  dimethyl sulfoxide (DMSO) is a solvent with anti-inflammatory and bacteriostatic activity; it produces analgesia and nerve  blockade,  diuresis,  cholinesterase  inhibition, vasodilation, and muscle relaxation. DMSO also has the  unique  capability  to  penetrate  living  tissues without causing significant damage. It has been used to enhance bladder absorption of chemotherapeutic agents such as cisplatin, pirarubicin, and doxorubicin [21,22] . In addition, DMSO is approved by the US Food and   Drug   Administration   for   the   treatment   of interstitial  cystitis  and  up  to  50%  (vol/vol)  DMSO can safely be instilled in the bladder of patients. 6.    Recent developments in physical approaches Drugs absorption through the bladder wall and drug concentrations   at   the   target   site   (detrusor)   are important  determinants  of  efficacy,  but  passive diffusion  (PD)  of  drugs  across  the  urothelium  is complex and not easily defined. european urology 50 (2006) 1183–1193 1185 </p>
                                        
                                            <p>5. was  a  useful  method  to  determine  tissue  concen- trations of oxybutynin [39] . The procedure was then applied for tissue extraction and the determination of other agents ( Table 1 ). The objectives of experimental studies were also to  analyse  the  effects  of  electric  current  both  on bladder tissues and on the chemical structure of the drug being used. Di Stasi et al. observed that EMDA did not alter the chemical structure of RTX, lidocaine and epinephrine, oxybutynin, or MMC and did not induce any damage to the exposed bladder tissues [34,38,40–42] , thus making this method a promising tool for the treatment of detrusor overactivity and superficial  bladder  cancer  and  for  inducing  local anaesthesia. Furthermore, through in vitro studies the authors demonstrated that EMDA significantly increased the transport rates of several drugs into the  bladder  wall,  as  compared  to  simple  PD.  Two recent   laboratory   studies   investigated   both   the transport  rates  of  RTX  into  pig  bladder  wall  after either PD or EMDA and the best conditions for the stability   of   RTX   stock   solutions [34,35] .   These authors  showed  that  the  application  of  electric current   significantly   reduced   the   variability   in transport rates of RTX as compared to PD and that glass storage in the dark and at low temperatures did not  alter  the  stability  of  the  drug [34,35] .  These results could allow better results with RTX intrave- sical treatment. From  a  clinical  standpoint  ( Table  2 ),  EMDA  has been  demonstrated  to  significantly  increase  the transport  rates  of  several  drugs  into  the  bladder wall,  as  compared  to  simple  PD [32,43–45] .  Stenzl et al. found that five of six patients were tumour free after  a  follow-up  of  10–16  mo,  after  electromotive administration   of d -aminolevulinic   acid   ( d -ALA) solution [44] . In this study, d -ALA was used for the photodynamic diagnosis and therapy of superficial bladder  tumours.  The  response  rate  in  high-risk superficial   bladder   cancer   was   improved   with increased bladder uptake of MMC following electro- motive administration [32] . Intravesical electromo- tive administration of both 5 and 15 mg oxybutynin significantly increased cystometric bladder capacity and  significantly  reduced  the  first  volume  for  the onset  of  uninhibited  detrusor  contractions,  and duration and maximum pressure of these contrac- tions,  in  patients  with  neurogenic  detrusor  over- activity [29,30] .  Clinical  reports  demonstrated  that intravesical  EMDA  of  local  anaesthetics  produced sufficient anaesthesia to allow transurethral resec- tion of bladder tumours [45,46] , to perform botuli- num toxin A injections into the detrusor muscle [47] , to  administer  intravesical  capsaicin [48] ,  and  to determine   cystodistention   in   the   treatment   of refractory interstitial cystitis and chronic noninfec- tious cystitis [49–51] . 6.1.   Side-effects Fatal side-effects have never been reported during or after  treatment  with  EMDA.  Hinkel  and  Pannek reported systemic neurologic alterations after EMDA in two older patients treated for chronic noninfec- tious   cystitis,   probably   related   to   epinephrine systemic  absorption [52] .  No  clinical  evidence  of lidocaine  toxicity  has  been  reported,  and  serial serum lidocaine levels measured in a few patients were innocuous [46] . No haematologic toxicity was observed after application of MMC by PD or EMDA [31,32] , and no systemic side-effects were observed after oxybutynin 15 mg with EMDA application [30] . The  most  frequently  reported  side-effect  is  the appearance of a transient skin erythema at the site of abdominal electrode or a tingling sensation on the abdomen during treatment ( Table 2 ). 6.2.   Costs It  has  been  reported  that,  compared  to  spinal  or general anaesthesia, the local anaesthesia induced by  lidocaine  with  EMDA  saves  around  15%  of  the costs [47] . This treatment modality allows clinicians to  perform  bladder  distention  also  in  an  office setting, with equivalent results to distention under general anaesthesia and potentially less morbidity and  lower  costs [53,54] .  The  cost  per  patient  was about $146 Cdn less with electromotive intravesical lidocaine   than   with   conventional   general/spinal anaesthesia [45] . Overall, the cost of the technique includes purchasing a generator ( ffi Euro 2500.00), a specially  designed  electrode  ( ffi Euro  250.00),  and anaesthetics  and  other  medications.  The  current generator  can  usually  be  used  for  at  least  100 treatments before needing replacement or repair. 7.    Recent developments in chemical approaches A  number  of  substances  have  been  developed  to increase  drug  transport  across  the  bladder  wall. Sasaki   reported   that   intravesical   instillation   of saponin before administering anticancer drugs (4 0 - O-tetrahydropyranyldoxorubicin  [THP])  can  cause vacuolisation and swelling of superficial cells, and the  concentration  of  THP  in  bladder  tissues  was significantly higher than that of untreated animals. In  any  case,  no  difference  was  found  in  plasma [55,56] . european urology 50 (2006) 1183–1193 1187 </p>
                                        
                                            <p>8. Certain peptides called cell - penetrating peptides or protein transduction domains have been shown to posses the ability to translocate macromolecular drugs  across  the  blood–brain  barrier  and  mem- branes of other cells [57] . However, these peptides are  not  cell  selective  and  thus  represent  a  poor choice for systemic use. One of the authors of the present study (M.B.C.) examined the effect of short-length transactivators of  transcription  peptides,  deriving  from  immuno- deficiency virus, for the intravesical administration of  macromolecular  drugs  such  as  peptide  nucleic acids   (PNAs).   PNAs   have   been   used   for   their ‘‘antisense’’ effect in various studies; in other words, they bind to RNA and completely block transcription [58] .  PNAs  show  superior  binding  properties  and higher stability in biologic fluids such as urine, over a   wide   pH   range,   as   compared   to   traditional oligonucleotides and ribozymes [59] . 7.1.   Sustained drug delivery Sustained intravesical delivery of drugs can ensure the continuous presence of the drug in the bladder without  needing  intermittent  catheterisation,  and drug concentration in the bladder would be constant without any peaks and valleys. It is also plausible to expect increased efficacy with increased duration of direct contact between the drug and the abnormal urothelium [60] . A  simple  and  sensible  approach  for  sustained intravesical drug delivery is prolonged infusion into the bladder. This technique has often been applied to achieve slow and sustained release of drugs inside the   bladder.   Prolonged   instillation   of   RTX   was recently  demonstrated  as  a  feasible  procedure  for treating  interstitial  cystitis [61] .  RTX  was  infused through a suprapubic 5F mono-pigtail catheter for 10 d at the flow rate 25 m l/h with the help of an infusion pump. Patients were evaluated 30 d after the end of infusion and after 3 mo. A 30% decrease in frequency and  a  3-fold  reduction  of  nocturia  was  observed, with a significant reduction of pelvic pain for at least 6 mo after the end of infusion. A similar approach was previously applied for local therapy of prosta- glandins  in  the  treatment  of  cyclophosphamide- induced cystitis in patients [62,63] . A 100-ml irriga- tion  of  5 m g/ml  prostaglandin  E 2 (PGE 2 )  into  the bladder for 3 h completely freed a 40-yr-old patient of all symptoms within 24 h [64] . Forming a drug depot inside the bladder appears to be an attractive option over prolonged infusion. Aqueous  solutions  of  poly(ethylene  glycol-b-[DL- lactic acid-co-glycolic acid]-b-ethylene glycol) (PEG- PLGA-PEG) triblock copolymers form a free-flowing solution at room temperature and become a viscous gel at body temperature of 37 8 C [65] . Its formulation does not require organic solvent, and the products from  bioerosion  of  the  biocompatible  polymer  are nontoxic  PEG,  glycolic  acid,  and  lactic  acid [66] . Thermosensitive hydrogel formed by PEG-PLGA-PEG has been used for in situ gel formation for a depot of hydrophobic and hydrophilic drugs following sub- cutaneous administration in rats [67] . The triblock copolymer  was  used  for  sustaining  the  residence time  of  hydrophobic  drugs  in  rat  bladder  after  its instillation  at  room  temperature.  The  kinetics  of drug excretion were studied by fluorescence mea- surement  of  urine  after  instilling  fluorescein  iso- thiocyanate-loaded  hydrogel.  The  increased  urine concentration   over   a   period   of   time   implies increased penetration into the bladder tissue. The therapeutic benefit of sustained delivery afforded by thermosensitive   hydrogel   was   demonstrated   by delivering misoprostol, an anti-inflammatory drug. It was able to protect the bladder against cyclopho- sphamide-induced cystitis [68] . 7.2.   Liposomes Liposomes were first studied in England in 1961 by Bangham [69] and, since then, they have become a versatile tool of study in biology, biochemistry, and medicine.  Liposomes  are  artificial  spherical  vesi- cles consisting of an aqueous core enclosed in one or more phospholipid layers, used as drug carriers and loaded with a great variety of molecules such as small  drug  molecules,  proteins,  nucleotides,  and even  plasmids [70] .  Previously,  liposomes  were shown to improve the aqueous solubility of hydro- phobic   drugs   such   as   paclitaxel   (Taxol)   and amphotericin; a recent report by the laboratory of one of the authors in the United States discussed the use of liposomes as vehicles for capsaicin and evaluated their potential as a vehicle for intrave- sical delivery in rats [71] . Liposomes were able to deliver  capsaicin  with  efficacy  similar  to  that  of ethanolic  saline,  but  toxicity  to  the  bladder  was drastically reduced [72] . Liposomes  are  versatile  drug  delivery  vehicles due  to  the  flexibility  of  their  compositions.  Lipo- somes were used for intracellular delivery of anti- cancer drugs and biologics into the bladder cancer cell  line.  Use  of  multilamellar  liposomes  proved favourable  in cell culture studies and the antipro- liferative capacity of interferon a (IFN- a ) in resistant bladder  cancer  cell  lines  was  improved  by  using liposomes   as   a   delivery   vehicle.   Instillation   of liposomes encapsulated radiolabelled IFN- a or radio- labelled liposomes into mouse bladder was able to european urology 50 (2006) 1183–1193 1190 </p>
                                        
                                            <p>1. Review – Voiding Dysfunction New Frontiers in Intravesical Therapies and Drug Delivery Antonella Giannantoni a , * , Savino M. Di Stasi b , Michael B. Chancellor c , Elisabetta Costantini a , Massimo Porena a a Department of Urology, University of Perugia, Perugia, Italy b Department of Urology, ‘‘Tor Vergata’’ University of Rome, Rome, Italy c McGowan Institute of Regenerative Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States european urology 50 (2006) 1183–1193 available at www.sciencedirect.com journal homepage: www.europeanurology.com Article info Article history: Accepted August 16, 2006 Published online ahead of print on August 30, 2006 Keywords: Electric current Intravesical drug administration Permeability Sustained delivery Abstract Objectives: The intravesical route permits site-specific delivery of drugs with a reduced  side-effect  profile  as  compared  to  oral  delivery  systems,  either  by avoiding first-pass metabolism or by obtaining a local effect. We investigated mechanisms related to urothelium permeability and new physical and chemical developments in intravesical drug delivery that potentially permit successful treatment of several bladder dysfunction. Methods: A literature review. Results: Pharmacologic agents increasing urothelial permeability and useful for clinical purposes have been described, such as dimethylsulfoxide, prota- mine sulphate, chitosan, and nystatin. Among physical approaches, electro- motive  drug  administration  appears  to  be  more  effective  than  intravesical passive  diffusion  in  delivering  drugs  through  the  urothelium  into  deeper layers  of  the  bladder.  Experimental  and  clinical  reports  demonstrated  that electric  current  significantly  increases  the  transport  of  local  anaesthetics, mytomicin C, oxybutynin, resiniferatoxin, epinephrine, and dexamethasone. Among new chemical approaches, cell-penetrating peptides posses the ability to translocate macromolecular drugs across membranes of urothelial  cells. The  therapeutic  benefits  of  sustained  delivery  afforded  by  thermosensitive hydrogel, which forms a depot for hydrophilic and hydrophobic drugs, have been   demonstrated   by   delivering   anti-inflammatory   drugs.   Liposomes improve the aqueous solubility of several hydrophobic drugs such as taxol, amphotericin, and capsaicin. Conclusions: Electromotive drug administration, new in situ delivery systems, and bioadhesive liposomes may make it possible to extend intravesical ther- apy and drug administration to many bladder diseases. Research to expand knowledge of the chemical and physical properties of the bladder and pro- cesses regulating drug transport across biologic membranes is needed to make this a reality. # 2006 European Association of Urology. Published by Elsevier B.V. All rights reserved. *  Corresponding author. Department of Urology, University of Perugia, Policlinico Monteluce, Via Brunamonti 51, 06122 Perugia, Italy. Tel. +39 075 5783979; Fax: +39 075 5726123. E-mail address: <a href="../../cdn-cgi/l/email-protection.html" class="__cf_email__" data-cfemail="e786808e8689938889a78b8e85829588c98e93">[email&#160;protected]</a> (A. Giannantoni). 0302-2838/$ – see back matter # 2006 European Association of Urology. Published by Elsevier B.V. All rights reserved.    doi: 10.1016/j.eururo.2006.08.025 </p>
                                        
                                            <p></p>
                                        
                                    
                                </div>
                                <div role="tabpanel" class="tab-pane fade" id="statistic" slide-url="new-frontiers-in-intravesical-therapies-and-drug-delivery-2006-53.html">
                                    <div class="row">
                                        <div class="col-lg-4">
                                            <h4 class="mt0 oe_slides_statistics_title">Nézetek</h4>
                                            <ul class="list-group">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">1127</span>
                                                    <i class="fa fa-play"></i> Total Views
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">851</span>
                                                    <i class="fa fa-circle-o"></i> Website Views
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">276</span>
                                                    <i class="fa fa-code"></i> Embedded Views
                                                </li>
                                            </ul>
                                        </div>

                                        <div class="col-lg-4">
                                            <h4 class="mt0 oe_slides_statistics_title">Műveletek</h4>
                                            <ul class="list-group">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="total-share">0</span>
                                                    <i class="fa fa-share-alt"></i> Social Shares
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">0</span>
                                                    <i class="fa fa-thumbs-up"></i> Likes
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">0</span>
                                                    <i class="fa fa-thumbs-down"></i> Nemkedvelések
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">0</span>
                                                    <i class="fa fa-comments-o"></i> Comments
                                                </li>
                                            </ul>
                                        </div>

                                        <div class="col-lg-4">
                                            <h4 class="mt0 oe_slides_statistics_title">Share count</h4>
                                            <ul class="list-group">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="facebook-badge">0</span>
                                                    <i class="fa fa-facebook-square"></i> Facebook
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="twitter-badge">0</span>
                                                    <i class="fa fa-twitter-square"></i> Twitter
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="linkedin-badge">0</span>
                                                    <i class="fa fa-linkedin-square"></i> LinkedIn
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="google-badge">0</span>
                                                    <i class="fa fa-google-plus-square"></i> Google+
                                                </li>
                                            </ul>
                                        </div>
                                    </div>
                                    <div class="row">
                                        <div class="col-lg-12">
                                            <h4 class="mt0"> Embeds
                                                <span class="badge badge-pill float-right">
                                                    2
                                                </span>
                                            </h4>
                                            <ul class="list-group" style="height: 150px;overflow: auto;">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">2</span>
                                                    hbs.hu
                                                </li><li class="list-group-item">
                                                    <span class="badge badge-pill">2</span>
                                                    odoo.hbs.hu
                                                </li>
                                            </ul>
                                        </div>
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
                <div class="col-xl-4 col-lg-4 col-md-12 col-12">
                    <ul class="nav nav-tabs" role="tablist">
                        <li class="nav-item"><a aria-controls="related" href="#related" class="nav-link active" data-toggle="tab">Kapcsolódó</a></li>
                        <li class="nav-item"><a aria-controls="most_viewed" href="#most_viewed" class="nav-link" data-toggle="tab">Most Viewed</a></li>
                    </ul>
                    <div class="tab-content">
                        <div role="tabpanel" id="related" class="tab-pane active mt4">
                            <div class="card">
                                <ul class="list-unstyled card-body">
                                    
                                    
                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="cuaj-5-6-e136-17.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/17/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="cuaj-5-6-e136-17.html"><h6 class="mb-1">cuaj-5-6-e136</h6></a>
            <small class="text-muted">
                1558 Views . <timeago class="timeago" datetime="2019-10-31 13:27:48.254982"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/18/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html"><h6 class="mb-1">Minimally invasive device for intravesical instillation-Lovasz-2019-International_Journal_of_Urology</h6></a>
            <small class="text-muted">
                1504 Views . <timeago class="timeago" datetime="2019-10-31 13:28:10.125299"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="cikk-a-neurourology-and-urodynamics-ban-2018-19.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/19/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="cikk-a-neurourology-and-urodynamics-ban-2018-19.html"><h6 class="mb-1">Cikk a Neurourology and Urodynamics-ban 2018.</h6></a>
            <small class="text-muted">
                1473 Views . <timeago class="timeago" datetime="2019-10-31 13:28:23.618732"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-treatment-checklist-20.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/20/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-treatment-checklist-20.html"><h6 class="mb-1">IC-BPS Treatment Checklist</h6></a>
            <small class="text-muted">
                1498 Views . <timeago class="timeago" datetime="2019-10-31 13:28:50.163748"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-diagnostic-algorhytm-21.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/21/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-diagnostic-algorhytm-21.html"><h6 class="mb-1">IC-BPS diagnostic algorhytm.</h6></a>
            <small class="text-muted">
                1487 Views . <timeago class="timeago" datetime="2019-10-31 13:29:57.450898"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="glycosaminoglycan-therapy-for-bladder-diseases-22.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/22/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="glycosaminoglycan-therapy-for-bladder-diseases-22.html"><h6 class="mb-1">Glycosaminoglycan Therapy for Bladder Diseases</h6></a>
            <small class="text-muted">
                1384 Views . <timeago class="timeago" datetime="2019-10-31 13:30:10.980936"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="essic-2017-budapest-abstracts-23.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/23/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="essic-2017-budapest-abstracts-23.html"><h6 class="mb-1">ESSIC 2017 Budapest abstracts</h6></a>
            <small class="text-muted">
                1463 Views . <timeago class="timeago" datetime="2019-10-31 13:30:38.129948"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="prevalence-of-symptoms-of-bladder-pain-syndrome-2011-24.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/24/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="prevalence-of-symptoms-of-bladder-pain-syndrome-2011-24.html"><h6 class="mb-1">Prevalence of Symptoms of Bladder Pain Syndrome 2011</h6></a>
            <small class="text-muted">
                1303 Views . <timeago class="timeago" datetime="2019-10-31 13:30:57.131521"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="the-urinary-microbiota-of-men-and-women-and-its-changes-in-women-during-bacterial-vaginosis-and-antibiotic-treatment-2017-25.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/25/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="the-urinary-microbiota-of-men-and-women-and-its-changes-in-women-during-bacterial-vaginosis-and-antibiotic-treatment-2017-25.html"><h6 class="mb-1">The urinary microbiota of men and women and its changes in women during bacterial vaginosis and antibiotic treatment. 2017</h6></a>
            <small class="text-muted">
                1361 Views . <timeago class="timeago" datetime="2019-10-31 13:35:55.689470"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="interstitial-cystitis-associated-urinary-metabolites-identified-by-mass-spectrometry-based-metabolomics-analysis-2016-26.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/26/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="interstitial-cystitis-associated-urinary-metabolites-identified-by-mass-spectrometry-based-metabolomics-analysis-2016-26.html"><h6 class="mb-1">Interstitial Cystitis-Associated Urinary Metabolites Identified by Mass-Spectrometry Based Metabolomics Analysis. 2016</h6></a>
            <small class="text-muted">
                1298 Views . <timeago class="timeago" datetime="2019-10-31 13:36:14.959707"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="pentosan-polysulfate-sodium-for-therapy-of-ic-urology-1990-27.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/27/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="pentosan-polysulfate-sodium-for-therapy-of-ic-urology-1990-27.html"><h6 class="mb-1">PENTOSAN POLYSULFATE SODIUM FOR THERAPY of IC Urology 1990</h6></a>
            <small class="text-muted">
                1413 Views . <timeago class="timeago" datetime="2019-10-31 13:37:27.415502"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="interstitial-cystitis-intravesical-therapy-tau-06-s2-s171-2017-28.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/28/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="interstitial-cystitis-intravesical-therapy-tau-06-s2-s171-2017-28.html"><h6 class="mb-1">Interstitial cystitis intravesical therapy tau-06-S2-S171 2017</h6></a>
            <small class="text-muted">
                1367 Views . <timeago class="timeago" datetime="2019-10-31 13:38:04.204366"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="novel-targeted-bladder-drug-delivery-systems-rru-7-169-2015-29.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/29/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="novel-targeted-bladder-drug-delivery-systems-rru-7-169-2015-29.html"><h6 class="mb-1">Novel targeted bladder drug-delivery systems rru-7-169 2015</h6></a>
            <small class="text-muted">
                1488 Views . <timeago class="timeago" datetime="2019-10-31 13:38:18.425299"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulfate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-2016-bmjopen-2015-009669-30.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/30/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulfate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-2016-bmjopen-2015-009669-30.html"><h6 class="mb-1">Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections 2016 bmjopen-2015-009669</h6></a>
            <small class="text-muted">
                1220 Views . <timeago class="timeago" datetime="2019-10-31 13:38:52.835202"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-treatment-with-highly-concentrated-hyaluronic-acid-and-chondroitin-sulphate-in-patients-with-recurrent-urinary-tract-infections-results-from-a-multicentre-survey-cuaj-9-10-e721-31.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/31/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-treatment-with-highly-concentrated-hyaluronic-acid-and-chondroitin-sulphate-in-patients-with-recurrent-urinary-tract-infections-results-from-a-multicentre-survey-cuaj-9-10-e721-31.html"><h6 class="mb-1">Intravesical treatment with highly-concentrated hyaluronic acid and chondroitin sulphate in patients with recurrent urinary tract infections- Results from a multicentre survey.cuaj-9-10-e721</h6></a>
            <small class="text-muted">
                1387 Views . <timeago class="timeago" datetime="2019-10-31 13:39:08.628954"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-and-glycosaminoglycans-replacement-therapy-2015-tau-04-06-638-32.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/32/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-and-glycosaminoglycans-replacement-therapy-2015-tau-04-06-638-32.html"><h6 class="mb-1">IC_BPS and glycosaminoglycans replacement therapy 2015 tau-04-06-638</h6></a>
            <small class="text-muted">
                1250 Views . <timeago class="timeago" datetime="2019-10-31 13:39:22.993300"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="managing-chronic-bladder-diseases-with-the-administration-of-exogenous-glycosaminoglycans-an-update-on-the-evidence-2016-urology-33.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/33/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="managing-chronic-bladder-diseases-with-the-administration-of-exogenous-glycosaminoglycans-an-update-on-the-evidence-2016-urology-33.html"><h6 class="mb-1">Managing chronic bladder diseases with the administration of exogenous glycosaminoglycans- an update on the evidence 2016 Urology</h6></a>
            <small class="text-muted">
                1388 Views . <timeago class="timeago" datetime="2019-10-31 13:40:52.836690"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="hyaluronic-acid-and-its-composites-as-a-local-antimicrobial-antiadhesive-barrier-2017-jbjiv02p0063-34.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/34/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="hyaluronic-acid-and-its-composites-as-a-local-antimicrobial-antiadhesive-barrier-2017-jbjiv02p0063-34.html"><h6 class="mb-1">Hyaluronic Acid and Its Composites as a Local Antimicrobial-Antiadhesive Barrier 2017.jbjiv02p0063</h6></a>
            <small class="text-muted">
                1310 Views . <timeago class="timeago" datetime="2019-10-31 13:45:41.648470"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="evidence-based-criteria-for-the-pain-of-ic-bps-in-women-2008-nihms43157-35.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/35/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="evidence-based-criteria-for-the-pain-of-ic-bps-in-women-2008-nihms43157-35.html"><h6 class="mb-1">Evidence-based criteria for the pain of IC_BPS in women 2008 nihms43157</h6></a>
            <small class="text-muted">
                1300 Views . <timeago class="timeago" datetime="2019-10-31 13:45:59.326213"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-glycosaminoglycan-replacement-with-chondroitin-2015-article-306-36.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/36/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-glycosaminoglycan-replacement-with-chondroitin-2015-article-306-36.html"><h6 class="mb-1">Intravesical Glycosaminoglycan Replacement with Chondroitin_2015_Article_306</h6></a>
            <small class="text-muted">
                1358 Views . <timeago class="timeago" datetime="2019-10-31 13:46:19.773972"></timeago>
            </small>
        </div>
    </li>

                                    
                                </ul>
                            </div>
                        </div>
                        <div role="tabpanel" id="most_viewed" class="tab-pane  mt4">
                            <div class="card">
                                <ul class="list-unstyled card-body">
                                    
                                    
                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="sugarvedo-ruhazat-ismerteto-3.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/3/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="sugarvedo-ruhazat-ismerteto-3.html"><h6 class="mb-1">Sugárvédő ruházat ismertető</h6></a>
            <small class="text-muted">
                3284 Views . <timeago class="timeago" datetime="2018-10-20 14:31:25.547995"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="op-set-system-5.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/5/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="op-set-system-5.html"><h6 class="mb-1">OP Set System</h6></a>
            <small class="text-muted">
                3044 Views . <timeago class="timeago" datetime="2018-11-16 13:38:03.543744"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="kompresszios-polya-felhelyezese-8.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/8/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="kompresszios-polya-felhelyezese-8.html"><h6 class="mb-1">Kompressziós pólya felhelyezése</h6></a>
            <small class="text-muted">
                2846 Views . <timeago class="timeago" datetime="2018-11-16 13:39:25.884480"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="kotszer-polya-l-r-6.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/6/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="kotszer-polya-l-r-6.html"><h6 class="mb-1">Kötszer Pólya L&amp;R</h6></a>
            <small class="text-muted">
                2643 Views . <timeago class="timeago" datetime="2018-11-16 13:38:35.611223"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="nedves-sebkezeles-flyer-l-r-7.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/7/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="nedves-sebkezeles-flyer-l-r-7.html"><h6 class="mb-1">Nedves sebkezelés flyer L&amp;R</h6></a>
            <small class="text-muted">
                2438 Views . <timeago class="timeago" datetime="2018-11-16 13:38:59.835920"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="pdb-actico-ulcersys-liner-10.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/10/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="pdb-actico-ulcersys-liner-10.html"><h6 class="mb-1">PDB_Actico UlcerSys Liner</h6></a>
            <small class="text-muted">
                2324 Views . <timeago class="timeago" datetime="2018-11-16 13:39:54.728282"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="scican-statim-g4-2.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/2/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="scican-statim-g4-2.html"><h6 class="mb-1">SciCan STATIM G4</h6></a>
            <small class="text-muted">
                2321 Views . <timeago class="timeago" datetime="2018-10-20 14:10:02.671163"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="pdb-actico-ulcersys-9.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/9/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="pdb-actico-ulcersys-9.html"><h6 class="mb-1">PDB_Actico UlcerSys</h6></a>
            <small class="text-muted">
                2209 Views . <timeago class="timeago" datetime="2018-11-16 13:39:42.488113"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="urostill-hasznalati-utmutato-v1-1-12.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/12/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="urostill-hasznalati-utmutato-v1-1-12.html"><h6 class="mb-1">UroStill_hasznalati_utmutato_v1.1</h6></a>
            <small class="text-muted">
                2038 Views . <timeago class="timeago" datetime="2019-10-31 13:22:24.531510"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="koronavirus-jarvany-61.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/61/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="koronavirus-jarvany-61.html"><h6 class="mb-1">KORONAVIRUS JARVANY</h6></a>
            <small class="text-muted">
                1774 Views . <timeago class="timeago" datetime="2020-04-09 15:16:22.317496"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="scican-statim-g4-1.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/1/image_thumb.jpg"/>
        </a>
        <div class="media-body">
            <a href="scican-statim-g4-1.html"><h6 class="mb-1">SciCan Statim G4</h6></a>
            <small class="text-muted">
                1708 Views . <timeago class="timeago" datetime="2018-10-20 14:09:31.661802"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="new-aiding-device-for-self-instillation-v2-16.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/16/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="new-aiding-device-for-self-instillation-v2-16.html"><h6 class="mb-1">New_aiding_device_for_self-instillation_v2</h6></a>
            <small class="text-muted">
                1690 Views . <timeago class="timeago" datetime="2019-10-31 13:23:48.863175"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="kitpack-11.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/11/image_thumb.jpg"/>
        </a>
        <div class="media-body">
            <a href="kitpack-11.html"><h6 class="mb-1">Kitpack</h6></a>
            <small class="text-muted">
                1684 Views . <timeago class="timeago" datetime="2018-11-16 14:52:39.736537"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="icbps-szoszedet-14.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/14/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="icbps-szoszedet-14.html"><h6 class="mb-1">ICBPS_SZÓSZEDET</h6></a>
            <small class="text-muted">
                1618 Views . <timeago class="timeago" datetime="2019-10-31 13:23:06.826135"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-faq-s-and-appropriate-answers-mumbai-2019-15.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/15/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-faq-s-and-appropriate-answers-mumbai-2019-15.html"><h6 class="mb-1">IC - FAQ-s and appropriate answers Mumbai 2019</h6></a>
            <small class="text-muted">
                1612 Views . <timeago class="timeago" datetime="2019-10-31 13:23:19.219912"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="urostill-users-manual-v1-1-13.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/13/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="urostill-users-manual-v1-1-13.html"><h6 class="mb-1">UroStill_Users_Manual_v1.1</h6></a>
            <small class="text-muted">
                1605 Views . <timeago class="timeago" datetime="2019-10-31 13:22:47.677753"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="l-r-corporate-film-4.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/4/image_thumb.jpg"/>
        </a>
        <div class="media-body">
            <a href="l-r-corporate-film-4.html"><h6 class="mb-1">L&amp;R Corporate Film</h6></a>
            <small class="text-muted">
                1601 Views . <timeago class="timeago" datetime="2018-11-14 15:53:51.760680"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="cuaj-5-6-e136-17.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/17/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="cuaj-5-6-e136-17.html"><h6 class="mb-1">cuaj-5-6-e136</h6></a>
            <small class="text-muted">
                1558 Views . <timeago class="timeago" datetime="2019-10-31 13:27:48.254982"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/18/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html"><h6 class="mb-1">Minimally invasive device for intravesical instillation-Lovasz-2019-International_Journal_of_Urology</h6></a>
            <small class="text-muted">
                1504 Views . <timeago class="timeago" datetime="2019-10-31 13:28:10.125299"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-treatment-checklist-20.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/20/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-treatment-checklist-20.html"><h6 class="mb-1">IC-BPS Treatment Checklist</h6></a>
            <small class="text-muted">
                1498 Views . <timeago class="timeago" datetime="2019-10-31 13:28:50.163748"></timeago>
            </small>
        </div>
    </li>

                                    
                                </ul>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    
                </main>
                <footer class="bg-light o_footer">
                    <div id="footer" class="oe_structure oe_structure_solo">
      <section class="s_text_block pb8 pt40">
        <div class="container">
          <div class="row" style="border-top: solid 1px #ddd; padding-top: 30px;">
            <div class="col-lg-4">
              <h5>További tartalmak</h5>
              <ul class="list-unstyled">
                <li>
                  <a href="../../blog/hirek-esemenyek-1.html" data-original-title="" title="" aria-describedby="tooltip310735">Hírek</a>
                  <br/>
                  <a href="../../adatkezelesi-tajekoztato.html">Adatkezelési tájékoztató</a>
                </li>
                <li>
                  <br/>
                </li>
              </ul>
            </div>
            <div class="col-lg-4" id="connect">
              <h5>Elérhetőségek</h5>
              <ul class="list-unstyled">
                <li>
                  <i class="fa fa-phone"></i>
                  <span data-note-id="2">+36 1 452 1700</span>
                </li>
                <li>
                  <i class="fa fa-envelope"></i>
                  <span><a href="../../cdn-cgi/l/email-protection.html" class="__cf_email__" data-cfemail="056c6b636a456d67762b6d70">[email&#160;protected]</a></span>
                </li>
              </ul>
              <p> </p>
            </div>
            <div class="col-lg-4">
              <h5>
                <span>HBS Medical</span>
                <small> – <a href="../../aboutus.html" data-original-title="" title="" aria-describedby="tooltip425138">Kapcsolat</a></small>
              </h5>
              <p>&nbsp;<br/></p>
            </div>
          </div>
        </div>
      </section>
    </div>
  <div class="o_footer_copyright">
            <div class="container">
                <div class="row">
                    <div class="col-lg-6 text-muted text-center text-md-left">
                        <span>Copyright &copy;</span> <span itemprop="name">HBS Medical</span>
                        
    

                    </div>
                    <div class="col-lg-6 text-right o_not_editable">
                        
    <!--<div class="o_brand_promotion text-muted">
        Az oldalt készítette:
        <a href="https://eyssen.hu/" target="_blank"><img src="../../web/image/606/eyssen_logo_blue.png" width="120"/></a>
    </div>-->

                    </div>
                </div>
            </div>
        </div>
    </footer>
            </div>
        <script data-cfasync="false" src="../../cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script id="tracking_code">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','https://www.google-analytics.com/analytics.js','ga');

            ga('create', _.str.trim('UA-52898474-1'), 'auto');
            ga('send','pageview');
        </script>
    
        
            </body>
        
<!-- Mirrored from hbs.hu/slides/slide/new-frontiers-in-intravesical-therapies-and-drug-delivery-2006-53 by HTTrack Website Copier/3.x [XR&CO'2014], Mon, 31 May 2021 16:08:11 GMT -->
</html>
    
    
